Tirzepatide (Mounjaro, Zepbound) is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management and chronic weight management
During your consultation, your health profile will be fully assessed to find the best-adapted treatment and ensure all factors including insurance and personal preference are considered
No, not everyone experiences fatigue
These effects often diminish over time, but monitoring is crucial to ensure patient safety and comfort
It is also possible to have an allergic reaction to Victoza
Khaldoon Al-Humood has given lectures and received honorariums from Medtronic, Abbott, Boehringer Ingelheim, AstraZeneca, Pfizer, Bristol Myers Squibb (BMS), Novartis, and Servier